by Brook White | May 6, 2021 | Blog
Members of the Parkinson’s Foundation and the Parkinson’s Study Group (PSG), including VeraSci Senior Clinical Director of Movement Disorders Dr. Travis Turner, recently published a consensus statement titled “Expediting telehealth use in clinical research studies:... by Brook White | Apr 30, 2021 | Posters
Presented at the International Society for CNS Clinical Trials and Methodology (ISCTM) Annual Scientific Meeting Virtual Edition, April 6-9, 2021 While episodic memory impairment is often the hallmark of mild cognitive impairment (MCI) due to Alzheimer’s disease... by Brook White | Apr 26, 2021 | Posters
Presented at the American Academy of Neurology Virtual Annual Meeting, April 17-22, 2021 The VRFCAT-SL was administered to a sample of 29 patients with Parkinson’s disease during clinical neuropsychological evaluation. Based on the analysis presented in this... by Brook White | Apr 7, 2021 | Blog
The Movement Disorder Society (MDS) recently developed and validated a new scale for assessing non-motor fluctuations in Parkinson’s disease patients. The Non-Motor Fluctuations Assessment Questionnaire (NoMoFA) is a patient-reported outcome measure that seeks to... by Brook White | Mar 22, 2021 | Blog
Psychedelics are a group of drugs that facilitate the experience of non-ordinary states of consciousness through the activation of serotonin 5-HT2A receptors. This group includes psilocybin (a molecule present in 200+ mushroom species), lysergic acid diethylamide...